← Back to Search

Other

Mid dose ANAVEX2-73 for Alzheimer's Disease

Phase 2 & 3
Waitlist Available
Research Sponsored by Anavex Life Sciences Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 0, 4, 12, 24, 36, and 48
Awards & highlights

Study Summary

This study is evaluating whether a drug called ANAVEX2-73 can improve cognition and function in people with Alzheimer's disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 0, 4, 12, 24, 36, and 48
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 0, 4, 12, 24, 36, and 48 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition)
ADCS-ADL (Activities of Daily Living)
Secondary outcome measures
Dementia
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
Other outcome measures
Blood assessment
CSF assessment
Number of participants with change of brain volume assessed by MRI
+2 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Mid dose ANAVEX2-73Experimental Treatment1 Intervention
Mid dose active once daily orally
Group II: High dose ANAVEX2-73Experimental Treatment1 Intervention
High dose active once daily orally
Group III: Placebo oral capsulePlacebo Group1 Intervention
Placebo dose once daily orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
High dose ANAVEX2-73
2018
Completed Phase 3
~650
Mid dose ANAVEX2-73
2018
Completed Phase 3
~650

Find a Location

Who is running the clinical trial?

Anavex Australia Pty Ltd.Industry Sponsor
4 Previous Clinical Trials
710 Total Patients Enrolled
Anavex Germany GmbHIndustry Sponsor
4 Previous Clinical Trials
806 Total Patients Enrolled
Anavex Canada Ltd.UNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
2018. "ANAVEX2-73 for Treatment of Early Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03790709.
~75 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top